Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Founded on Midwest values, our Cincinnati-based company is people-focused, always looking for ways to benefit our customers,shareholders, and employees. Our company was built on strong work ethic, honesty, and a desire to help others.
Our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedicaltechnologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.
OUR MISSION
Always looking forward, we continually stay up-to-date on developing news and trends in the pharmaceutical industry. We are always looking for products, drugs and technologies that will benefit our customers. As a publicly-traded company, our shareholders are also important to us. Our goal is to make decisions that directly benefit them and show our appreciation for their support in our company.
As a company with its roots in female health and wellness, we are committed to delivering breakthrough products and services that truly improve daily living. Our logo, the beautiful and strong Calla Lily, represents our mission and goals.
Callitas Health, INC- (OTCQB: MPHMF: LILY, ) was Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J's LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive and is in the research and development and business development process for its other OTC products, cannabis dosing technologies and orphan drug technologies.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in linked press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.